Vitiligo;Vitiligo

Anais Brasileiros de Dermatologia

Volumn 79, Issue 3, 2004, Pages 335-351

  Steiner, Denise ^a,b,h   Tadeu Villas, Ricardo ^e   Bedin, Valcinir ^c   Steiner, Tatiana ^f,g   Brito Moraes, Mirella ^d  

^a FACULDADE DE MEDICINA DE JUNDIAÍ   (Brazil)

^b School of Medicine   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d Clínica Stöckli SP

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f FACULDADE DE MEDICINA DO ABC   (Brazil)

^g Disciplines of Psychiatry and Medical Psychology Medical School Fundação ABC   (Brazil)

^h Clinica Stöckli   (Brazil)

Author keywords

Hypopigmentation; Vitiligo

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; BERGAPTEN; BETAMETHASONE; CALCIUM; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FOLIC ACID; IMIQUIMOD; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; KHELLIN; LEVAMISOLE; MELAGENIN; METHOXSALEN; PHENOL; PHENYLALANINE; PIMECROLIMUS; PLACENTA EXTRACT; PREDNISOLONE; PSORALEN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACNE; ASEPTIC NECROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DEPIGMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; DRUG CHOICE; DRUG CONTRAINDICATION; EMOTIONAL STRESS; EPIDEMIOLOGICAL DATA; EPIGASTRIC PAIN; ERYTHEMA; GENETIC PREDISPOSITION; HUMAN; INSOMNIA; MECHANICAL STRESS; NAUSEA; ONSET AGE; OSTEOPOROSIS; PHOTOTHERAPY; PHOTOTOXICITY; PHYSICAL STRESS; PRURITUS; PUVA; REVIEW; SEX RATIO; SIDE EFFECT; SKIN ATROPHY; SKIN BLEEDING; STEROID THERAPY; STRIA; TELANGIECTASIA; THYROID DISEASE; ULTRAVIOLET B RADIATION; VITILIGO; VOMITING; WEIGHT GAIN;

EID: 3242691612     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0365-05962004000300010     Document Type: Review

References (80)

1. Lerner AB, Nordlund JJ. Vitiligo: What is it? Is it important?. J Am Med Assoc 1978;239:1183-1187.
2. Nordlund JJ, Majumder PP. Recent investigations on vitiligo vulgaris: advances in clinical research. Dermatol Clin 1997;15:69-78.
3. El-Mofty AM. Vitiligo and Psoralens. Pergamon Press: New York, 1968.
4. Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: Multilocus recessivity cross-validated. Am J Hum Genetic 1994;55:981-990.
5. Nodlund JJ. Hypopigmentation, vitiligo and melanoma: New data, more enigmas. Arch Dermatol 1998;123:1005-1011.
6. Foley NR, Lowe NJ, Misheloff E, Tiwari JL. Association of HLA-DR4 with vitiligo. J Am Acad Dermatol 1983;8:39-40.
7. Behl PN, Bhatia RK. Treatment of vitiligo with autologous thin Thiersch's grafts. Int J Dermatol 1973;12:329-331.
8. Slominski A, Paul R, Bomriski A. Hypothesis: possible role of melatonin receptors in vitiligo. J R Soc Med 1989;82:539-541.
9. Barona MI et al. An epidemiological case-control study in a population with vitiligo. J Am Acad Dermatol 1995;33(4): 621-625
10. Abdel-Nasser MB et al. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Research 1994;7:1-8.
11. Porter J, Beuf AH, Lerner AB, Nodlund JJ. Response to cosmetic disfigurement; patients with vitiligo. Cutis 1987;39:493-494.
12. Nath SK, Manjumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet 1994;55:981-990.
13. Majumder PP, Nordlund JJ, Li CC. Pattern of familial aggregation of vitiligo. Arch Dermatol. 1993;129:994-998.
14. Chen IT, Jimbow K. Comparison in expression of tyrosinase, TRP-1, and c-Kit between normal human melanocytes and "vitiligo"melanocytes. Pigment cell Research 1994;24 (suppl 3).
15. Norris DA, Kissinger RM, Naughton GM. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular toxicity. J Invest Dermatol 1998;90:783-789.
16. Ortonne JP, Bose SK. Vitiligo: where do we stand? Pigment Cell Research 6, 61-72.
17. Bystryn, J.C. & (1997) Immune mechanisms in vitiligo. Clin Dermatol 1993;15:853-861
18. Bystryn JC, Naughton GK. The significance of vitiligo antibodies. J Dermatol 1985;12:1-9.
19. Zamani M et al. Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol 2001;145:90-94.
20. Bystryn JC, Xie Z, Neoplastic hypomelanoses. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, eds. The Pigmentary System: Physiology and Pathophysiology, New York: Oxford University Press, 647-662.
21. Harning R, Cui J, Bystryn J-C. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991;97:1078-1080.
22. Norris DA, Capin L, Muglia JJ et al. Enhaced susceptibility of melanocytes of different immunologic effector mechanisms in vitro: potential mechanisms for postinflammatory hypopigmentation and vitiligo. Pigment Cell Research 1998:113-123.
23. Fishman P et al. Vitiligo antibodies are effective against melanoma. Cancer 1993;72:2365-2369.
24. Naughton GK, Reggiardo MD, Bystryn J-C. Correlation between vitiligo antibodies and extent of dispigmentation in vitiligo. J Am Acad Dermatol 1986;15:978-981.
25. Ziegler I. Production of pterdines during hematopoiesis and T-lymphocyte proliferation-potencial participation in the control of cytokine signal transmission. Medicinal Research Reviews 1998; 10:95-114.
26. Bleehen SS et al. Despigmentation of skin with 4-isopropyl-catechol, mercaptoamines, and other compounds. J Invest Dermatol 1968;50:103-117.
27. Riley PA. Mechanisms of pigment cell toxicity produced by hydroxyanisole. J Pathol 1970;101:163-169.
28. Lerner AB. On the etiology of vitiligo and gray hair. Am J Med 1971;51:141-147.
29. Reedy MV et al. Regulation of melanoblast migration and differentiation. In: The Pigmentary System Physiology And Pathophysiology. New York: Oxford University Press, 1998:75-95.
30. Barnes L.Vitiligo and the Vogt-Koyanagi- Harada syndrome. Dermatol Clin 1988;6:229-239.
31. Nellhaus G. Acquired unilateral vitiligo and poliosis of the head and subacute encephalitis with partial recovery. Neurology 1970;20:961-974.
32. Schallreuter KU et al. Vitiligo and other disease: coexistence or true association? Hamburg study on 321 patients. Dermatology 1994;188:269-275.
33. Davis MD et al. 7-tetrahydrobiopterin, a natural occurring analogucof tetrahydrobiopterin is a cofator for, and a potencial inhibtor of the aromatic amino acid hydrolases. National Academy of Sciences, USA 89, 1992:10108-10113.
34. Lei X-D et al. Expression of 4a- carbinolamine dehydratasein human epidermal keratinocytes. Bichem Biophys Res Commun 1997;238:556-559.
35. Cormane RH, Siddiqui AH, Schutgens RBH. Phenylalanine and UVA light for the treatment of vitiligo. Arch Dermatol Res 1985;277:126-130.
36. Hand SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol 1996;36:671-674.
37. Jaisankar TJ et al. Vitiligo in children. Int J Dermatol 1993;31: 621-623.
38. Pal SK et al. Thyroid function in vitiligo. Clinica Chimica Acta 1980;106:331-332.
39. Grimes PE et al. Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 1983;119:300-303.
40. Korkij W et al. Tissue-specific autoantibodies and autoimmune disorders in vitiligo and alopecia areata: a retrospective study. J Cutan Pathol 1984;11:522-530.
41. Lerner AB. Vitiligo. J Invest Dermatol 1959;32:285-310.
42. Le Poole IC et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol 1993;100:816-822.
43. Hu F et al. In vitro studies of vitiligo. J Invest Dermatol 1959; 33:267-280.
44. Falabella R. Idiopathic gruttate hypomelanosis. Dermatol Clin 1988;6:241-247.
45. Staricco RG. Amelanotic melanocytes in the outer sherth of the hair follicles. J Invest Dermatol 1959;33:295-297.
46. Cui J, Shen LY, Wang GC. Role of hair folicles in the repigmentation of vitiligo. J Invest Dermatol 1991;97:410-416.
47. Kandil E. Treatment of localized vitiligo with intradermal injection of triamcinolone acetonide. Dermatologica 1970; 140:195-206.
48. Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984;120:631-635.
49. Koga M. Vitiligo: A new classification and therapy. Br J Dermatol; 97:255-261.
50. Visitha LK, Singh G. Vitiligo and intralesional steroids. Indian J Med Res 1979;69:308-311.
51. Hann SK et al. Systemic steroids suppress antimelanocyte antibodies in vitiligo. J Cutan Med Surg 1997;1:193-195.
52. Pasricha JS et al. Oral Mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 1993;31:753-757.
53. Kim SM et al. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999;38:546-550.
54. Parrish JA, Fitzpatrick T et al. Photochemotherapy of vitiligo. Use of orally administered psoralens and a high-intensity long-wave ultraviolet light system. Arch Dermatol 1976; 112(11):1531-1534.
55. Grimes PE, Minus HR et al. Determination of optimal topical photochemotherapy for vitiligo. J Am Acad Dermatol 1982; 7(6):771-778.
56. Halder RM, Grimes PE et al. Childhood Vitiligo. J Am Acad Dermatol 1987;16 (5pt1):948-954.
57. Ortonne, JP, Mosher DV et al. Vitiligo and Other Hypomelanoses. Plenum Publisshing Co., New York. 1993
58. Skouge JW, Morison WL et al. Autografting and PUVA. A combination therapy for vitiligo. J Dermatol Surg Oncol 1992; 18(5):357-360.
59. Bleehen SS. The treatament of vitiligo with topical corticosteroids. Light and electron-microscopic studies. Br J Dermatol 1996;94 (Suppl 12):43-50.
60. Falabella R, Arrunátegui A, Barona MI, Alzate A. The mini-grafting tet for vitiligo: Detection of stable lesions for melanocyte transplatation. J Am Acad Dermatol 1995;32:228-232.
61. a, Nordlund JJ, Lerner A. Extracelular granular material and degeneration of keratinocytes in normally pigmented epidermis of patientes with vitiligo. J Invest Dermatol 1982;79:321-330.
62. Halder R, Pham H, Breadon J, Johnson B. Micropigmentation for the treatment of vitiligo. J Dermatol Surg Oncol 1989;15:1092-1098.
63. Schallreuter KU, Pittelkow MR. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991;97:1081-1085.
64. Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatament of vitiligo with a topical application of pseudocatalase and calcium in combination with short term UVB exposure: a case on 33 patients. Dermatology 1995;190:223-229.
65. Maresca V, Rocella M, Camera E et al. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol 1997;109:310-313.
66. Patipa M. Eyelid tattooing. Deramtol Clin 1987;5:335-348.
67. Calanchini-Postizzi E, Frenk E. Long-term actinic damage in sun-exposed vitiligo and mormally pigmented skin. Dermatologica 1987;174:266-271.
68. Abdel-Malek A, Swope V, Dixon K. A possible unique mechanism for UVB induced hyperpigmentation. International Pigment Cell Conference; London, 26-30 September. p 5. 1993
69. Nordlund JJ. Melagenina and vitiligo (Reply). Dermatology 1992; 184(2):154-155.
70. Morliere P, Honigsmann H, Averbeck D et al. Phototherapeutic, photobiologic and photosensitizing properties of khellin. J Invest Dermatol 1998;90:720-724.
71. Antoniou C, Schulpis H, Michas T et al. Vitiligo therapy with oral and topical phenylalanine with UVA exposure. Int J Dermatol 1998;184(2):153-155.
72. Greiner D, Ochsendorf FR, Milbradt R. Vitiligo- Therapie mit Phenylalanin/UVA. Katammnestiche Untersuchungen nach funf Jahren. Hautarzt 1994;45:460-463.
73. Montes LF et al. Folic acid and vitamin B 12 in vitiligo: a nutritional approach. Cutis 1992;50:39-42
74. Monk B. Topical flurouracil in vitiligo. Arch Dermatol 1985; 121:25-26.
75. Picardo M, Passi S, Morrone A, Grandineti M, Di Carlo A, Ippolito F. Antioxidant status in the blood of patients with active vitiligo. Pigment Cell Research 1994;7:110-115.
76. Nakamura T, Pinnell SR, Darr D et al. Vitamin C abrogates the deleterious effects of UVB radiation on cutaneous immunity by a mechanism that does not depend on THF-alfa. J Invest Dermatol 1997;109:20-24.
77. Pasricha JS, Khera V. Effect of prolonged treatament with levamisole on vitiligo with limited and low-spreading disease. Int J Dermatol 1994;33(8):584-587.
78. Gokhale BB. Cyclophosphamide and vitiligo. Int J Dermatol 1979;18:92.
79. Grimes PE, Soriane T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002;47(5):789-91.
80. Tanghetti EA. Tacrolimus ointrent 0,1% produces repigmentation in patients with vitiligo: results of a prospective patients series. Cutis (Cutis) 2003;71(2):158-62.